Prolactinomas and nonfunctioning adenomas: preoperative diagnosis of tumor type using serum prolactin and tumor size

View More View Less
  • 1 University of Louisville School of Medicine, University of Louisville, Louisville, Kentucky;
  • 2 Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; and
  • 3 Pacific Neuroscience Institute at the John Wayne Cancer Institute, Santa Monica, California
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

OBJECTIVE

Prolactinoma and nonfunctioning adenoma (NFA) are the most common sellar pathologies, and both can present with hyperprolactinemia. There are no definitive studies analyzing the relationship between the sizes of prolactinomas and NFAs and the serum prolactin level. Current guidelines for serum prolactin level cutoffs to distinguish between pathologies are suboptimal because they fail to consider the adenoma volume. In this study, the authors attempted to describe the relationship between serum prolactin level and prolactinoma volume. They also examined the predictive value that can be gained by considering tumor volume in differentiating prolactinoma from NFA and provide cutoff values based on a large sample of patients.

METHODS

A retrospective analysis of consecutive patients with prolactinomas (n = 76) and NFAs (n = 217) was performed. Patients were divided into groups based on adenoma volume, and the two pathologies were compared.

RESULTS

A strong correlation was found between prolactinoma volume and serum prolactin level (r = 0.831, p < 0.001). However, there was no significant correlation between NFA volume and serum prolactin level (r = −0.020, p = 0.773). Receiver operating characteristic curve analysis of three different adenoma volume groups was performed and resulted in different serum prolactin level cutoffs for each group. For group 1 (≤ 0.5 cm3), the most accurate cutoff was 43.65 μg/L (area under the curve [AUC] = 0.951); for group 2 (> 0.5 to 4 cm3), 60.05 μg/L (AUC = 0.949); and for group 3 (> 4 cm3), 248.15 μg/L (AUC = 1.0).

CONCLUSIONS

Prolactinoma volume has a significant impact on serum prolactin level, whereas NFA volume does not. This finding indicates that the amount of prolactin-producing tissue is a more important factor regarding serum prolactin level than absolute adenoma volume. Hence, volume should be a determining factor to distinguish between prolactinoma and NFA prior to surgery. Current serum prolactin threshold level guidelines are suboptimal and cannot be generalized across all adenoma volumes.

ABBREVIATIONS AUC = area under the curve; HPT = highest pretreatment; NFA = nonfunctioning adenoma; ROC = receiver operating characteristic; TSS = transsphenoidal surgery.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Correspondence Edward R. Laws: Brigham and Women’s Hospital, Boston, MA. elaws@bwh.harvard.edu.

INCLUDE WHEN CITING Published online June 14, 2019; DOI: 10.3171/2019.3.JNS19121.

Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

  • 1

    Bergsneider M, Mirsadraei L, Yong WH, Salamon N, Linetsky M, Wang MB, : The pituitary stalk effect: is it a passing phenomenon? J Neurooncol 117:477484, 2014

    • Search Google Scholar
    • Export Citation
  • 2

    Bevan JS, Burke CW, Esiri MM, Adams CB: Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement. Am J Med 82:2932, 1987

    • Search Google Scholar
    • Export Citation
  • 3

    Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, : Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265273, 2006

    • Search Google Scholar
    • Export Citation
  • 4

    Chahal J, Schlechte J: Hyperprolactinemia. Pituitary 11:141146, 2008

  • 5

    Chanson P, Borson-Chazot F, Chabre O, Estour B: Drug treatment of hyperprolactinemia. Ann Endocrinol (Paris) 68:113117, 2007

  • 6

    Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S: Management of clinically non-functioning pituitary adenoma. Ann Endocrinol (Paris) 76:239247, 2015

    • Search Google Scholar
    • Export Citation
  • 7

    Cheng JS, Salinas R, Molinaro A, Chang EF, Kunwar S, Blevins L, : A predictive algorithm for evaluating elevated serum prolactin in patients with a sellar mass. J Clin Neurosci 22:155160, 2015

    • Search Google Scholar
    • Export Citation
  • 8

    Colao A: Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 23:575596, 2009

  • 9

    Couldwell WT, Rovit RL, Weiss MH: Role of surgery in the treatment of microprolactinomas. Neurosurg Clin N Am 14:8992, 2003

  • 10

    Couldwell WT, Weiss MH: Medical and surgical management of microprolactinoma. Pituitary 7:3132, 2004

  • 11

    Hong JW, Lee MK, Kim SH, Lee EJ: Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma. Endocrine 37:140147, 2010

    • Search Google Scholar
    • Export Citation
  • 12

    Huang Y, Ding C, Zhang F, Xiao D, Zhao L, Wang S: Role of prolactin/adenoma maximum diameter and prolactin/adenoma volume in the differential diagnosis of prolactinomas and other types of pituitary adenomas. Oncol Lett 15:20102016, 2018

    • Search Google Scholar
    • Export Citation
  • 13

    Iglesias P, Díez JJ: Macroprolactinoma: a diagnostic and therapeutic update. QJM 106:495504, 2013

  • 14

    Jethwa PR, Patel TD, Hajart AF, Eloy JA, Couldwell WT, Liu JK: Cost-effectiveness analysis of microscopic and endoscopic transsphenoidal surgery versus medical therapy in the management of microprolactinoma in the United States. World Neurosurg 87:6576, 2016

    • Search Google Scholar
    • Export Citation
  • 15

    Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, : Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf) 65:524529, 2006

    • Search Google Scholar
    • Export Citation
  • 16

    Kawaguchi T, Ogawa Y, Tominaga T: Diagnostic pitfalls of hyperprolactinemia: the importance of sequential pituitary imaging. BMC Res Notes 7:555, 2014

    • Search Google Scholar
    • Export Citation
  • 17

    Liu JK, Couldwell WT: Contemporary management of prolactinomas. Neurosurg Focus 16(4):E2, 2004

  • 18

    Lucas JW, Bodach ME, Tumialan LM, Oyesiku NM, Patil CG, Litvack Z, : Congress of Neurological Surgeons systematic review and evidence-based guideline on primary management of patients with nonfunctioning pituitary adenomas. Neurosurgery 79:E533E535, 2016

    • Search Google Scholar
    • Export Citation
  • 19

    Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, : Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273288, 2011

    • Search Google Scholar
    • Export Citation
  • 20

    Nomikos P, Buchfelder M, Fahlbusch R: Current management of prolactinomas. J Neurooncol 54:139150, 2001

  • 21

    Ntali G, Capatina C, Fazal-Sanderson V, Byrne JV, Cudlip S, Grossman AB, : Mortality in patients with non-functioning pituitary adenoma is increased: systematic analysis of 546 cases with long follow-up. Eur J Endocrinol 174:137145, 2016

    • Search Google Scholar
    • Export Citation
  • 22

    Penn DL, Burke WT, Laws ER: Management of non-functioning pituitary adenomas: surgery. Pituitary 21:145153, 2018

  • 23

    Ross RJ, Grossman A, Bouloux P, Rees LH, Doniach I, Besser GM: The relationship between serum prolactin and immunocytochemical staining for prolactin in patients with pituitary macroadenomas. Clin Endocrinol (Oxf) 23:227235, 1985

    • Search Google Scholar
    • Export Citation
  • 24

    Schlechte JA: Clinical practice. Prolactinoma. N Engl J Med 349:20352041, 2003

  • 25

    Smith TR, Hulou MM, Huang KT, Gokoglu A, Cote DJ, Woodmansee WW, : Current indications for the surgical treatment of prolactinomas. J Clin Neurosci 22:17851791, 2015

    • Search Google Scholar
    • Export Citation
  • 26

    Turner HE, Adams CB, Wass JA: Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists? Eur J Endocrinol 140:4347, 1999

    • Search Google Scholar
    • Export Citation
  • 27

    Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB: Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 44:254263, 1999

    • Search Google Scholar
    • Export Citation
  • 28

    Vance ML, Thorner MO: Prolactinomas. Endocrinol Metab Clin North Am 16:731753, 1987

  • 29

    Wong A, Eloy JA, Couldwell WT, Liu JK: Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges. J Clin Neurosci 22:15621567, 2015

    • Search Google Scholar
    • Export Citation
  • 30

    Wong A, Eloy JA, Couldwell WT, Liu JK: Update on prolactinomas. Part 2: Treatment and management strategies. J Clin Neurosci 22:15681574, 2015

    • Search Google Scholar
    • Export Citation
  • 31

    Zaidi HA, Cote DJ, Castlen JP, Burke WT, Liu YH, Smith TR, : Time course of resolution of hyperprolactinemia after transsphenoidal surgery among patients presenting with pituitary stalk compression. World Neurosurg 97:27, 2017

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 141 141 141
Full Text Views 63 63 63
PDF Downloads 45 45 45
EPUB Downloads 0 0 0